Sonoma Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, California.
Subscribe to see Sonoma Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Sonoma Biotherapeutics, Inc. is a biotechnology company headquartered in South San Francisco, United States. It has raised at least $335M across the 3 funding rounds on record. Its most recent funding round raised $265M in July 2021. Xcout tracks 5 named people at Sonoma Biotherapeutics, Inc., including Stephen Dilly (President and Chief Executive Officer).
As of 17 November 2026. Source: Xcout Intel.
At least $335M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $265M | — | |
| — | $30M | 14 named | |
| — | $40M | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 14 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of Sonoma Biotherapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
TRex Bio, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. The company focuses on discovering and developing precision therapeutics to treat moderate-to-severe immune-mediated diseases by targeting regulatory T cells.
Ouro Medicines is a biotechnology company headquartered in South San Francisco, California, developing immune reset therapeutics for chronic immune-mediated diseases.
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
GentiBio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with an additional office in Seattle, Washington, developing engineered regulatory T cell (Treg) therapies to cure Type 1 diabetes and other autoimmune diseases.
Tizona Therapeutics, Inc. is a privately held immunology company founded in 2015 and headquartered in South San Francisco, California. The company focuses on harnessing the power of the immune system to develop treatments.
SonoThera, Inc. is a biotechnology company headquartered in South San Francisco, California, focused on developing genetic medicines and advancing the field of gene therapy.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Sonoma Biotherapeutics, Inc.? Suggest a correction · Work at Sonoma Biotherapeutics, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.